CY2103B1 - Protein kinase c inhibitor - Google Patents

Protein kinase c inhibitor

Info

Publication number: CY2103B1
Authority: CY; Cyprus
Prior art keywords: inhibitor; protein kinase; kinase; protein
Prior art date: 1995-11-20

Application number

CY9800046A

Other languages

English (en)

Inventor

Gary Lowell Engel

Nagy Alphonse Farid

Margaret Mary Faul

Michael Robert Jirousek

Lori Ann Richardson

Leonard Larry Winnerosk

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-20

Filing date

1998-11-19

Publication date

2002-04-05

1998-11-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2002-04-05 Publication of CY2103B1 publication Critical patent/CY2103B1/xx

Links

101710175516 14 kDa zinc-binding protein Proteins 0.000 title 1
229940123924 Protein kinase C inhibitor Drugs 0.000 title 1
239000003881 protein kinase C inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CY9800046A 1995-11-20 1998-11-19 Protein kinase c inhibitor CY2103B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US697095P	1995-11-20	1995-11-20

Publications (1)

Publication Number	Publication Date
CY2103B1 true CY2103B1 (en)	2002-04-05

Family

ID=21723527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY9800046A CY2103B1 (en)	1995-11-20	1998-11-19	Protein kinase c inhibitor

Country Status (34)

Country	Link
US (3)	US5710145A (de)
EP (1)	EP0776895B1 (de)
JP (1)	JP3348859B2 (de)
KR (1)	KR100304210B1 (de)
CN (1)	CN1093759C (de)
AR (2)	AR004717A1 (de)
AT (1)	ATE172199T1 (de)
AU (1)	AU711125B2 (de)
BR (1)	BR9611724A (de)
CA (1)	CA2237221C (de)
CO (1)	CO4750823A1 (de)
CY (1)	CY2103B1 (de)
CZ (1)	CZ297524B6 (de)
DE (1)	DE69600784T2 (de)
DK (1)	DK0776895T3 (de)
EA (1)	EA000967B1 (de)
EG (1)	EG23871A (de)
ES (1)	ES2122764T3 (de)
HU (1)	HU226821B1 (de)
IL (1)	IL124417A (de)
MX (1)	MX9803792A (de)
MY (1)	MY118068A (de)
NO (1)	NO310196B1 (de)
NZ (1)	NZ323571A (de)
PE (1)	PE22798A1 (de)
PL (1)	PL184715B1 (de)
RO (1)	RO120074B1 (de)
SI (1)	SI0776895T1 (de)
TR (1)	TR199800759T2 (de)
TW (1)	TW403754B (de)
UA (1)	UA61897C2 (de)
WO (1)	WO1997018809A1 (de)
YU (1)	YU49315B (de)
ZA (1)	ZA969646B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
AR017200A1 (es)	1997-12-23	2001-08-22	Astrazeneca Ab	Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
KR100610127B1 (ko) *	1998-01-30	2006-08-09	다이소 가부시키가이샤	부탄트리올 유도체의 제조 방법
US6103712A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for asthma
US6291446B1 (en) *	1998-03-05	2001-09-18	Eli Lilly And Company	Therapeutic treatment for cytomegalovirus infection
US6103713A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for autoimmune diseases
US6225301B1 (en) *	1998-03-05	2001-05-01	Eli Lilly And Company	Therapeutic treatment for renal dysfunction
SE9800835D0 (sv)	1998-03-13	1998-03-13	Astra Ab	New Compounds
AU758241B2 (en) *	1998-03-13	2003-03-20	University Of British Columbia, The	Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en)	1998-03-13	1999-09-13	University Of British Columbia	Granulatimide compounds as g2 checkpoint inhibitors
US6706721B1 (en) *	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) *	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
TWI223598B (en) *	1998-06-22	2004-11-11	Pfizer Ireland Pharmaceuticals	An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
US6841567B1 (en) *	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en)	1999-05-21	2002-12-10	Astrazeneca Ab	Pharmaceutically active compounds
US6284783B1 (en)	1999-06-09	2001-09-04	The Uab Research Foundation	Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en)	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
US7087613B2 (en) *	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6852688B2 (en)	2000-03-10	2005-02-08	University Of Florida	Compositions for treating diabetic retinopathy and methods of using same
US6852510B2 (en)	2000-07-03	2005-02-08	Gala Design Inc	Host cells containing multiple integrating vectors
AU2001270252B2 (en) *	2000-07-03	2007-02-08	Catalent Pharma Solutions, Llc	Expression vectors
US20030224415A1 (en) *	2001-06-29	2003-12-04	Gala Design, Inc.	Selection free growth of host cells containing multiple integrating vectors
US6300106B1 (en) *	2000-11-22	2001-10-09	Ppg Industries Ohio, Inc.	Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US20040038304A1 (en) *	2002-03-28	2004-02-26	Gala Design, Inc.	Antibody libraries
US7384738B2 (en) *	2002-03-28	2008-06-10	Bremel Robert D	Retrovirus-based genomic screening
AU2003241398A1 (en) *	2002-05-06	2003-11-17	Washington University	Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
DE10244453A1 (de) *	2002-09-24	2004-04-01	Phenomiques Gmbh	Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) *	2003-01-10	2007-06-19	Board Of Trustees Of The Leland Stanford Junior University	Kinase inhibitors and associated pharmaceutical compositions and methods of use
DE602004025569D1 (de)	2003-06-18	2010-04-01	Tranzyme Pharma Inc	Makrozyklische motilin rezeptorantagonisten
US20050152942A1 (en) *	2003-12-23	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US20050221429A1 (en) *	2004-01-16	2005-10-06	Cardinal Health Pts, Llc	Host cells containing multiple integrating vectors comprising an amplifiable marker
CN1964706A (zh) *	2004-03-17	2007-05-16	拉斯·M·拉森	通过抑制视觉周期预防视网膜病
DE102004019413A1 (de) *	2004-04-19	2005-11-24	Phenos Gmbh	Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
WO2006071451A2 (en) *	2004-12-03	2006-07-06	The Regents Of The University Of California	Compounds that prevent macrophage apoptosis and uses thereof
WO2006068988A1 (en) *	2004-12-20	2006-06-29	Eli Lilly And Company	Combination therapy for vascular complications associated with hyperglycemia
US8034823B2 (en) *	2005-02-22	2011-10-11	Savvipharm Inc	Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
US8158586B2 (en) *	2005-04-11	2012-04-17	Pharmagap Inc.	Inhibitors of protein kinases and uses thereof
US8508369B2 (en)	2006-09-01	2013-08-13	Intermec Ip Corp.	RFID tag system with block coding, such as space-time block coding
AR069799A1 (es) *	2007-12-21	2010-02-17	Novartis Ag	Composicion farmaceutica
EP2181999A1 (de)	2008-11-03	2010-05-05	Zentiva, A.S.	Verfahren zur Herstellung von Ruboxistaurin
WO2010098888A1 (en) *	2009-02-27	2010-09-02	Massachusetts Institute Of Technology	Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
CA2795456A1 (en)	2010-03-30	2011-10-06	Novartis Ag	Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
RU2674995C2 (ru)	2012-11-29	2018-12-14	Новартис Аг	Фармацевтические комбинации
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en)	2016-12-19	2018-07-05	Chromaderm, Inc.	Methods of treating hyperpigmentation disorders
WO2018175302A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Polymer conjugates targeting c-src with reduced exposure
WO2018175340A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Reduced exposure conjugates modulating therapeutic targets
IL272246B2 (en)	2017-07-28	2026-01-01	Applied Therapeutics Inc	History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
KR20230005944A (ko)	2020-05-01	2023-01-10	어플라이드 테라퓨틱스 인크.	소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
KR20230128175A (ko) *	2022-02-25	2023-09-04	주식회사 온코크로스	루복시스타우린을 포함하는 항암용 조성물
CA3255435A1 (en)	2022-05-20	2023-11-23	Dermbiont, Inc.	Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5292747A (en) *	1990-08-07	1994-03-08	Hoffman-La Roche Inc.	Substituted pyrroles
WO1994007895A1 (en) *	1992-09-25	1994-04-14	Schering Corporation	Diindolo compounds and pharmaceutical compositions containing them
KR100340159B1 (ko) *	1993-12-07	2002-11-23	일라이 릴리 앤드 캄파니	단백질키나제c억제제
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors

1996
- 1996-11-18 ES ES96308318T patent/ES2122764T3/es not_active Expired - Lifetime
- 1996-11-18 WO PCT/US1996/018512 patent/WO1997018809A1/en not_active Ceased
- 1996-11-18 RO RO98-00955A patent/RO120074B1/ro unknown
- 1996-11-18 ZA ZA9609646A patent/ZA969646B/xx unknown
- 1996-11-18 US US08/749,607 patent/US5710145A/en not_active Expired - Lifetime
- 1996-11-18 EP EP96308318A patent/EP0776895B1/de not_active Expired - Lifetime
- 1996-11-18 SI SI9630038T patent/SI0776895T1/xx unknown
- 1996-11-18 PE PE1996000829A patent/PE22798A1/es not_active Application Discontinuation
- 1996-11-18 KR KR1019980703622A patent/KR100304210B1/ko not_active Expired - Fee Related
- 1996-11-18 BR BR9611724A patent/BR9611724A/pt not_active Application Discontinuation
- 1996-11-18 PL PL96326754A patent/PL184715B1/pl not_active IP Right Cessation
- 1996-11-18 CA CA002237221A patent/CA2237221C/en not_active Expired - Fee Related
- 1996-11-18 NZ NZ323571A patent/NZ323571A/xx not_active IP Right Cessation
- 1996-11-18 TW TW085114103A patent/TW403754B/zh not_active IP Right Cessation
- 1996-11-18 CN CN96198420A patent/CN1093759C/zh not_active Expired - Lifetime
- 1996-11-18 AT AT96308318T patent/ATE172199T1/de active
- 1996-11-18 YU YU60996A patent/YU49315B/sh unknown
- 1996-11-18 EA EA199800374A patent/EA000967B1/ru not_active IP Right Cessation
- 1996-11-18 DK DK96308318T patent/DK0776895T3/da active
- 1996-11-18 CZ CZ0150298A patent/CZ297524B6/cs not_active IP Right Cessation
- 1996-11-18 AU AU10548/97A patent/AU711125B2/en not_active Ceased
- 1996-11-18 JP JP51983697A patent/JP3348859B2/ja not_active Expired - Fee Related
- 1996-11-18 UA UA98052515A patent/UA61897C2/uk unknown
- 1996-11-18 DE DE69600784T patent/DE69600784T2/de not_active Expired - Lifetime
- 1996-11-18 TR TR1998/00759T patent/TR199800759T2/xx unknown
- 1996-11-18 IL IL12441796A patent/IL124417A/en not_active IP Right Cessation
- 1996-11-18 HU HU9903377A patent/HU226821B1/hu not_active IP Right Cessation
- 1996-11-19 CO CO96060835A patent/CO4750823A1/es unknown
- 1996-11-19 MY MYPI96004799A patent/MY118068A/en unknown
- 1996-11-19 EG EG102296A patent/EG23871A/xx active
- 1996-11-20 AR ARP960105255A patent/AR004717A1/es not_active Application Discontinuation
- 1996-11-20 AR ARP960105254A patent/AR004336A1/es not_active Application Discontinuation
1997
- 1997-11-07 US US08/966,081 patent/US6015807A/en not_active Expired - Lifetime
1998
- 1998-05-13 MX MX9803792A patent/MX9803792A/es unknown
- 1998-05-13 NO NO19982182A patent/NO310196B1/no not_active IP Right Cessation
- 1998-11-19 CY CY9800046A patent/CY2103B1/xx unknown
1999
- 1999-12-07 US US09/455,697 patent/US6117861A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IL124417A (en)	2002-11-10
AU1054897A (en)	1997-06-11
US5710145A (en)	1998-01-20
PE22798A1 (es)	1998-05-11
EG23871A (en)	2007-11-27
NO310196B1 (no)	2001-06-05
JP3348859B2 (ja)	2002-11-20
HUP9903377A3 (en)	2000-04-28
KR19990067596A (ko)	1999-08-25
ATE172199T1 (de)	1998-10-15
YU49315B (sh)	2005-06-10
WO1997018809A1 (en)	1997-05-29
CZ150298A3 (cs)	1998-12-16
KR100304210B1 (ko)	2001-11-05
US6015807A (en)	2000-01-18
CO4750823A1 (es)	1999-03-31
IL124417A0 (en)	1998-12-06
RO120074B1 (ro)	2005-08-30
YU60996A (sh)	1999-03-04
BR9611724A (pt)	1999-06-01
EP0776895A1 (de)	1997-06-04
SI0776895T1 (en)	1999-04-30
CZ297524B6 (cs)	2007-01-03
ES2122764T3 (es)	1998-12-16
PL326754A1 (en)	1998-10-26
AU711125B2 (en)	1999-10-07
CN1202825A (zh)	1998-12-23
EA000967B1 (ru)	2000-08-28
NZ323571A (en)	1998-12-23
AR004717A1 (es)	1999-03-10
JPH11500149A (ja)	1999-01-06
ZA969646B (en)	1998-05-18
HUP9903377A2 (hu)	2000-02-28
NO982182L (no)	1998-05-13
DK0776895T3 (da)	1999-06-23
CA2237221C (en)	2003-03-25
HU226821B1 (en)	2009-11-30
AR004336A1 (es)	1998-11-04
MX9803792A (es)	1998-09-30
DE69600784D1 (de)	1998-11-19
PL184715B1 (pl)	2002-12-31
TW403754B (en)	2000-09-01
EP0776895B1 (de)	1998-10-14
TR199800759T2 (xx)	2001-01-22
UA61897C2 (en)	2003-12-15
US6117861A (en)	2000-09-12
MY118068A (en)	2004-08-30
DE69600784T2 (de)	1999-04-08
NO982182D0 (no)	1998-05-13
CA2237221A1 (en)	1997-05-29
EA199800374A1 (ru)	1998-10-29
CN1093759C (zh)	2002-11-06

Publication	Publication Date	Title
EG23871A (en)	2007-11-27	Protein kinase c inhibitor
AU5324996A (en)	1996-10-16	Protein kinase c inhibitors
CY2561B1 (en)	2008-07-02	Protein kinase C inhibitors
PL321759A1 (en)	1997-12-22	Novel thrombosin inhibitors
AU7631496A (en)	1997-06-11	Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
PL330120A1 (en)	1999-04-26	Farnesilic protein transferase inhibitors
HUP9903694A3 (en)	2002-10-28	Medicines comprising rho kinase inhibitor
FI945706A7 (fi)	1995-06-08	Proteiinikinaasi C-inhibiittoreita
PL326863A1 (en)	1998-10-26	Thrombine inhibitors
AU3731293A (en)	1993-09-13	Protein kinase c inhibitor
AU6882598A (en)	1998-10-22	Protein kinase inhibitor
GB9510830D0 (en)	1995-07-19	Proteins
PL325013A1 (en)	1998-07-06	Profile endopepsidase inhibitors
GB2298252B (en)	1997-03-05	Procedure for gearbox-type determination
ZA949611B (en)	1996-06-03	Protein kinase C inhibitors
AU2591299A (en)	1999-09-15	Human protein kinase c inhibitor
GB9505865D0 (en)	1995-05-10	Hydrate Inhibitors
HUP9802561A3 (en)	1999-03-29	1-amino-3-benzyluracils
GB9519865D0 (en)	1995-11-29	Protein
GB9622436D0 (en)	1997-01-08	Protein
SI0657458T1 (en)	2001-12-31	Protein kinase C inhibitors
IL122092A0 (en)	1998-04-05	Protein kinase C inhibitors
GB9516227D0 (en)	1995-10-11	Re-textured protein
GB9511729D0 (en)	1995-08-02	Protein
GB9501486D0 (en)	1995-03-15	Protein